Sensus Healthcare, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joseph C. Sardano
- Full Time Employees
- 54
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 851 Broken Sound Parkway NW Boca Raton FL United States of America 33487
- IPO Date
- Jul 26, 2016
- CIK
- 0001494891
- Website
- sensushealthcare.com
- Similar Companies
- Business
- Sensus Healthcare, Inc. specializes in the development, manufacture, and commercialization of non-invasive and minimally invasive medical devices primarily for the treatment of non-melanoma skin cancer and keloids. Its core product portfolio includes the SRT-100 Vision™, SRT-100+™, and SRT-100 Vision™ systems, which utilize Superficial Radiation Therapy (SRT) technology to offer outpatient, non-surgical treatment options that are effective, painless, and minimize scarring. These devices deliver low-dose, targeted radiation to treat basal cell carcinoma, squamous cell carcinoma, and non-malignant tumors causing keloids, providing an alternative to surgery with faster patient recovery. In addition to its radiation therapy systems, the company expanded its offerings by acquiring mobile aesthetic laser companies in Florida and plans to develop its own FDA-cleared aesthetic laser products integrated with its proprietary Sentinel™ IT Solutions software for comprehensive asset management and patient data compliance. Recent major developments include the U.S. Centers for Medicare & Medicaid Services (CMS) establishing the first dedicated Current Procedural Terminology (CPT) codes for SRT and Image-Guided SRT (IG-SRT) treatments for non-melanoma skin cancer starting in 2026, significantly increasing reimbursement rates by over 300% per treatment fraction. This reimbursement milestone is expected to drive broader physician adoption and market expansion in dermatology and radiation oncology practices both within the United States and internationally. The company also expanded its executive leadership by appointing Eric Sachetta to the Board of Directors and expanded the role of President Michael Sardano to include Chief Commercial Officer responsibilities to focus on growth and recurring revenue models. Additionally, Sensus Healthcare strengthened its distribution channels through a partnership with Radiology Oncology Systems and expanded its presence in the UK and Ireland through a partnership with MIS Healthcare. Founded in 1990 and headquartered in Deerfield Beach, Florida, Sensus Healthcare operates primarily in the medical device industry focusing on oncology and dermatology business segments. It serves a customer base including dermatologists, oncologists, and healthcare institutions across the United States, China, the United Kingdom, Ireland, and other international markets. The company is committed to innovation and expanding access to non-invasive cancer treatments while integrating technology solutions that enhance treatment precision, patient outcomes, and practice efficiencies. Sensus Healthcare maintains a strong financial position with approximately $22 million in cash and no debt as of its latest reporting. It continues active clinical research and regulatory efforts supporting its Superficial Radiation Therapy technology and adjacent product lines to sustain growth and improve treatment options for skin cancer and related conditions. Overall, Sensus Healthcare stands as a medical technology company advancing non-invasive cancer care through its flagship SRT systems, recent strategic acquisitions, reimbursement milestones, and global market expansion initiatives with a focus on device innovation and software-enabled service offerings.
Sensus Healthcare Q1 Earnings Call Highlights
Sensus Healthcare Announces Amicable Resolution of Commercial Dispute with SkinCure Oncology
Sensus Healthcare, Inc. (SRTS) Q1 2026 Earnings Call Transcript
Sensus Healthcare Reports First Quarter 2026 Financial Results and Business Highlights
Sensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026
Sensus Healthcare (NASDAQ:SRTS) versus Adagio Medical (NASDAQ:ADGM) Head to Head Contrast
Brokerages Set Sensus Healthcare, Inc. (NASDAQ:SRTS) PT at $6.88
Sensus Healthcare Files Lawsuit Against SkinCure Oncology for Breach of Contract
Sensus Healthcare Introduces Sensus Link, Brings Advanced Operating Capabilities to the SRT-100™ Installed Base
Sensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT Technology
Sensus Healthcare, Inc. (SRTS) Q4 2025 Earnings Call Transcript
Sensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer
Sensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 2026
Sensus Healthcare (SRTS) Expected to Announce Earnings on Wednesday
Sensus Healthcare (NASDAQ:SRTS) vs. Envoy Medical (NASDAQ:COCH) Financial Contrast
Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Average Recommendation of “Hold” by Analysts
Sensus Healthcare to Hold Investor Meetings During JPM Week 2026 in San Francisco
Sensus Healthcare Appoints Larry Biscotti to its Board of Directors
Sensus Healthcare (NASDAQ:SRTS) vs. Venus Concept (NASDAQ:VERO) Head-To-Head Comparison
Sensus Healthcare Expands Role of President Michael Sardano to Include Chief Commercial Officer